ImmPACT Bio Granted FDA Fast Track Designation for IMPT-514 for the Treatment of Both Active, Refractory Lupus Nephritis and Systemic Lupus Erythematosus

IMPT-514 is the first CD19/CD20 CAR T-cell therapy in development for lupus Designed as a one-time treatment option, IMPT-514 has potential to reset the immune system through deep autoreactive B-cell depletion Dosing of first patient in Phase 1b/2 dose escalation trial expected in early…